AVEO Pharmaceuticals Inc. (AVEO)

1.96
0.02 1.01
NASDAQ : Health Technology
Prev Close 1.98
Open 1.96
Day Low/High 1.92 / 2.00
52 Wk Low/High 1.40 / 3.59
Volume 623.81K
Avg Volume 2.38M
Exchange NASDAQ
Shares Outstanding 125.35M
Market Cap 249.44M
EPS -0.60
P/E Ratio N/A
Div & Yield N.A. (N.A)
On being a Volvo investor in a Maserati market

On being a Volvo investor in a Maserati market

My philosophy is simple: buy low and sell high.

AVEO Oncology Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society Of Clinical Oncology Annual Meeting

AVEO Oncology Announces Presentation Of AV-203 Phase 1 Results At 2014 American Society Of Clinical Oncology Annual Meeting

AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3 (HER3) inhibitory antibody candidate.

AVEO Oncology To Present At The Jefferies Global Healthcare Conference

AVEO Oncology To Present At The Jefferies Global Healthcare Conference

AVEO Oncology (NASDAQ:AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2014 at 8:30AM (ET) in New York City.

AVEO Oncology Reports First Quarter 2014 Financial Results

AVEO Oncology Reports First Quarter 2014 Financial Results

AVEO Oncology (NASDAQ:AVEO) today reported its first quarter 2014 financial results and provided an update on its progress toward achieving its strategic plan.

AVEO Oncology To Report First Quarter 2014 Financial Results On May 7, 2014

AVEO Oncology To Report First Quarter 2014 Financial Results On May 7, 2014

AVEO Oncology (NASDAQ: AVEO) today announced that the company will release its financial results for the first quarter ended March 31, 2014 after market close on Wednesday, May 7, 2014.

AVEO And Biodesix Partner To Co-Develop And Commercialize Ficlatuzumab With A Companion Diagnostic For Treatment Of NSCLC

AVEO And Biodesix Partner To Co-Develop And Commercialize Ficlatuzumab With A Companion Diagnostic For Treatment Of NSCLC

AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced that they have entered into a worldwide agreement to develop and commercialize AVEO’s hepatocyte growth factor (HGF) inhibitory antibody ...

AVEO Regains Worldwide Rights To AV-203

AVEO Regains Worldwide Rights To AV-203

AVEO Oncology (NASDAQ: AVEO) today announced that it has regained worldwide rights to AV-203, a clinical-stage ErbB3 (HER3) inhibitory antibody candidate, from Biogen Idec.

AVEO Oncology Reports Full Year 2013 Financial Results And Outlines 2014 Strategic Plan

AVEO Oncology Reports Full Year 2013 Financial Results And Outlines 2014 Strategic Plan

AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2013 financial results and outlined its 2014 strategic plan and financial guidance.

AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Announces Timing For Conference Call To Discuss Year-End 2013 Financial Results And Provide Strategic Update For 2014

AVEO Oncology (NASDAQ: AVEO) today announced that financial results for the company’s fourth quarter and year ended December 31, 2013 will be released after the market closes on Thursday, March 13, 2014.

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO And Astellas To End Worldwide Collaboration & License Agreement For Development And Commercialization Of Tivozanib

AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today announced the companies will end their worldwide collaboration and license agreement for the development and commercialization of investigational...

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO And Astellas Discontinue Phase 2 Trial Of Tivozanib In Breast Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that AVEO and Astellas Pharma Inc.

Six charts that show why this market is overvalued

Six charts that show why this market is overvalued

By any number of measures this market is getting pricey.

Biotech 2013 by the Numbers: A Blockbuster Year

Biotech 2013 by the Numbers: A Blockbuster Year

The biotech sector closed 2013 up 65%, greatly outperforming the broader markets.

The Worst Biotech CEO of 2013 Is...

The Worst Biotech CEO of 2013 Is...

Vical's Vijay Samant is this year's CEO loser by a wide margin.

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Provides Update On Interim Analysis From Tivozanib Trial In Colorectal Cancer

AVEO Oncology (NASDAQ: AVEO) today announced that data from a planned interim analysis of the Phase 2 BATON ( Biomarker  Assessment of  Tivozanib in  ONcology) study in patients with colorectal cancer...

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Your Vote Counts: Who Is the Worst Biotech CEO of 2013?

Amarin, Ariad, Vical, Dendreon and Aveo. You get to decide which CEO deserves to wear the badge of shame.

AVEO Reports Third Quarter 2013 Financial Results

AVEO Reports Third Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported its third quarter 2013 financial results.

5 Biotech Stocks Under $10 for Your Watch List

5 Biotech Stocks Under $10 for Your Watch List

Keep an eye on these under-$10 biotech stocks.

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology To Present At The Morgan Stanley Global Healthcare Conference

AVEO Oncology (NASDAQ: AVEO) today announced that Tuan Ha-Ngoc, chief executive officer, is scheduled to present at the Morgan Stanley Global Healthcare Conference on Wednesday, September 11, 2013 at 12:55 p.

Aveo: Anatomy Of A Trade Gone Wrong

Aveo: Anatomy Of A Trade Gone Wrong

The FDA’s rejection of Aveo's Tivozanib is a stunner.

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology To Present At The Canaccord Genuity 33rd Annual Growth Conference

AVEO Oncology (NASDAQ: AVEO) today announced that David Johnston, chief financial officer, is scheduled to present at the Canaccord Genuity 33 rd Annual Growth Conference on Thursday, August 15, 2013 at 2:00 p.

AVEO Reports Second Quarter 2013 Financial Results

AVEO Reports Second Quarter 2013 Financial Results

AVEO Oncology (NASDAQ: AVEO) today reported second quarter 2013 financial results.

AVEO: Insiders Vs. Shorts

AVEO: Insiders Vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 06/28/2013 settlement date, and AVEO Pharmaceuticals, Inc. is one of the most shorted stocks of the Russell 3000, based on 5.59 "days to cover" versus the median component at 3.80.

FDA's Flawed Call On Aveo's Tivozanib

FDA's Flawed Call On Aveo's Tivozanib

The FDA has let down renal cancer patients with its Tivozanib decision.

The 5 Dumbest Things on Wall Street This Week: June 7

The 5 Dumbest Things on Wall Street This Week: June 7

Scotts Miracle-Gro CEO swears like a sailor, Aveo sinks like the Titanic, Sprint's captain tries to capsize the Dish CEO's offer and more.

5 Dumbest Things on Wall Street

5 Dumbest Things on Wall Street

Scotts Miracle-No!, Synta's Sorrow and Google's Porn Problem highlight Gregg Greenberg's 5 Dumbest list this week.

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's Future Depends on Triple-Negative Breast Cancer

Aveo's next chance to resurrect its flailing cancer drug will come in 2014/2015 with breast cancer study data.

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

Aveo Fires 140 Workers As Punishment For CEO's Incompetence

The failure of a kidney cancer drug won't stop Aveo executives from cashing future paychecks.

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle

Status quo reigns at struggling Aveo's shareholder meeting, but will planned changes include executive turnover?

TheStreet Quant Rating: D- (Sell)